ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Proteomic profiling identifies an oncogene ITGA2 and its downstream targets in gastric cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeGastric cancer is a leading cause of cancer-related mortality worldwide, with metastasis being the primary cause of death. Exosomes secreted by tumor cells are key mediators of intercellular communication and can prepare distant sites for metastasis by altering the local microenvironment. We hypothesized that exosomes released by gastric cancer cells deliver cargo that regulates specific proteins in recipient gastric cancer cells, thereby enhancing tumor progression and metastatic potential.
methodsHuman gastric cancer cell lines were treated with exosomes isolated from the conditioned medium of other gastric cancer cells. Differential proteomic analysis was performed to identify proteins significantly altered by exosome treatment. ITGA2 expression was validated in exosome-treated cells and in clinical gastric cancer tissues versus adjacent normal tissues using RT-qPCR and western blotting. The functional role of ITGA2 was assessed by siRNA-mediated knockdown, followed by MTT proliferation assays and fluorometric transwell assays for migration and invasion. A second proteomic analysis was conducted on ITGA2-knockdown versus control cells to identify downstream targets and affected pathways.
resultsExosome treatment significantly upregulated ITGA2 expression in recipient gastric cancer cells. ITGA2 was also markedly overexpressed in human gastric cancer tissues compared with adjacent normal mucosa. Knockdown of ITGA2 significantly suppressed cell proliferation, migration, and invasion. Proteomic profiling of ITGA2-knockdown cells revealed numerous differentially expressed proteins enriched in pathways related to cell adhesion, motility, extracellular matrix organization, and intercellular signaling.
conclusionExosomes derived from gastric cancer cells induce ITGA2 overexpression in recipient tumor cells, where ITGA2 functions as an oncogene that promotes proliferation, migration, and invasion. The downstream targets of ITGA2 implicate multiple pro-tumorigenic signaling networks, suggesting that the exosomes-ITGA2 axis may represent a novel therapeutic target in gastric cancer progression and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.